This discussion illustrates how a legacy manufacturer with extensive production expertise can become a leading innovator in the Orthobiologics Market. Click on the following video to learn more (14:43 min). A link to download the full transcript of the interview is also provided below.
SmartTRAK: This is David Shepard with SmartTRAK, GM and senior analyst for the orthobiologics and regenerative medicine segments. I'm joined by Harlan Adler, the CEO of Ranfac. Thank you very much for joining us. I appreciate it.
Harlan Adler: Yeah, of course. Thank you for having me.
So, obviously, a 130-year history with Ranfac, that's amazing. You recently acquired Cervos. That's the first time in the 130-year history that you've ever done an acquisition. Can you tell us a little bit about that and how things are going?
HA: In the Cervos acquisition, we were joint venture partners with Cervos Medical at the time. We did help launch the company. We were manufacturing all the products in Ranfac's facility, so I became very involved in that product line. I would say it became my baby, a little bit, inside of Ranfac. I think it was the right time for Ranfac. We felt that we had the company in a position where we were really ready, willing, and able to take that company to the next level. It's one thing to develop a product and manufacture a product, but then when you start working with some of the world's leading institutions, and they're incorporating your products into their everyday practice, you really get that validity. And that was something I was seeing with Cervos, it really helped me become that much more of a believer in this idea of utilizing a patient's own biology to help enhance healing. That's what the Cervos products do.
What we wanted to do was to scale the company to another level, and we felt that it was really only going to be able to be done efficiently and effectively if it was 100% owned by Ranfac. So, I sat down with the managing members from the other side of the joint venture at the time, and basically came to a mutual understanding that it made sense for this small autologous biologics company to be owned by a single company and made sense, as the manufacturer, for it to be us.
It was definitely a different direction from how Ranfac was really thinking about its own growth. Ranfac has really grown as a contract development and manufacturing organization. And we're very proud still to be manufacturing product across many, many specialties, and do quite a bit inside the orthopedic sector, specifically ...
Want to learn more about Ranfrac's first acquisition (Cervos) and their ongoing expansion into regenerative medicine and orthobiologics? Click the button below to download the full transcript of SmartTRAK GM/Sr Analyst, Orthobio & Regen David Shepherd's interview with Ranfac CEO Harlan Adler.
SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s proprietary methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK has to offer and see how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.